DETAILS, FICTION AND HEMGENIX

Variety of suitable patients: CDEC talked over the uncertainty in the quantity of clients with moderately intense to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical authorities consulted by CADTH indicated that some patients who will be categorised as owning moderate or average disorder could have a significant bleed